These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 22281299

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N, Harris NC, Roufail S, Paquet-Fifield S, Ishaq M, Streltsov VA, Williams SP, Karnezis T, Stacker SA, Achen MG.
    J Biol Chem; 2016 Dec 30; 291(53):27265-27278. PubMed ID: 27852824
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
    Liu B, Ma J, Wang X, Su F, Li X, Yang S, Ma W, Zhang Y.
    Anat Rec (Hoboken); 2008 Oct 30; 291(10):1227-35. PubMed ID: 18561194
    [Abstract] [Full Text] [Related]

  • 5. Molecular control of lymphatic metastasis.
    Achen MG, Stacker SA.
    Ann N Y Acad Sci; 2008 Oct 30; 1131():225-34. PubMed ID: 18519975
    [Abstract] [Full Text] [Related]

  • 6. Differential mRNA and tissue expression of lymphangiogenic growth factors (VEGF-C and -D) and their receptor (VEGFR-3) during tail regeneration in a gecko.
    Blacker HA, Orgeig S.
    J Comp Physiol B; 2012 Jan 30; 182(1):109-26. PubMed ID: 21800152
    [Abstract] [Full Text] [Related]

  • 7. High-density lipoproteins (HDL) are present in stenotic aortic valves and may interfere with the mechanisms of valvular calcification.
    Lommi JI, Kovanen PT, Jauhiainen M, Lee-Rueckert M, Kupari M, Helske S.
    Atherosclerosis; 2011 Dec 30; 219(2):538-44. PubMed ID: 21917259
    [Abstract] [Full Text] [Related]

  • 8. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.
    Cancer Res; 2008 Jun 15; 68(12):4754-62. PubMed ID: 18559522
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ, Opeskin K, Coso S, Wu D, Baldwin ME, Williams ED.
    Prostate; 2013 May 15; 73(6):563-72. PubMed ID: 23038639
    [Abstract] [Full Text] [Related]

  • 11. Quantitative analysis of lymphangiogenic markers in human gastroenteric tumor.
    Yuanming L, Feng G, Lei T, Ying W.
    Arch Med Res; 2007 Jan 15; 38(1):106-12. PubMed ID: 17174733
    [Abstract] [Full Text] [Related]

  • 12. Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas.
    Jenny B, Harrison JA, Baetens D, Tille JC, Burkhardt K, Mottaz H, Kiss JZ, Dietrich PY, De Tribolet N, Pizzolato GP, Pepper MS.
    J Pathol; 2006 May 15; 209(1):34-43. PubMed ID: 16523449
    [Abstract] [Full Text] [Related]

  • 13. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
    Liu ZY, Qiu HO, Yuan XJ, Ni YY, Sun JJ, Jing W, Fan YZ.
    Int J Oncol; 2012 Nov 15; 41(5):1762-72. PubMed ID: 22922710
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
    Maehana S, Nakamura M, Ogawa F, Imai R, Murakami R, Kojima F, Majima M, Kitasato H.
    Biomed Pharmacother; 2016 Dec 15; 84():660-665. PubMed ID: 27697638
    [Abstract] [Full Text] [Related]

  • 16. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [Abstract] [Full Text] [Related]

  • 17. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
    Lohela M, Heloterä H, Haiko P, Dumont DJ, Alitalo K.
    Am J Pathol; 2008 Dec 15; 173(6):1891-901. PubMed ID: 18988807
    [Abstract] [Full Text] [Related]

  • 18. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread.
    Schneider M, Büchler P, Giese N, Giese T, Wilting J, Büchler MW, Friess H.
    Int J Oncol; 2006 Apr 15; 28(4):883-90. PubMed ID: 16525637
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
    Onofri C, Losa M, Uhl E, Stalla GK, Renner U.
    Exp Clin Endocrinol Diabetes; 2008 Mar 15; 116(3):152-7. PubMed ID: 18205092
    [Abstract] [Full Text] [Related]

  • 20. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
    Von Marschall Z, Scholz A, Stacker SA, Achen MG, Jackson DG, Alves F, Schirner M, Haberey M, Thierauch KH, Wiedenmann B, Rosewicz S.
    Int J Oncol; 2005 Sep 15; 27(3):669-79. PubMed ID: 16077915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.